MiMedx Group, Inc

MDXG Healthcare Biotechnology

MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024. In the quarter to June 2026, revenue fell 34.7%, EPS fell 242.9%, free cash flow fell 174.8% and total debt fell 6.80%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

4.43 0.25 −5.34%
Market cap
$682.2M
P/E
111×
Fwd P/E
−31.2×
Dividend yield
—
F-score
5/9
Altman Z
9.38
Beneish M
−2.68
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
2.88% 13.77% 21.61% 19.44%

+8 more TTM periods

Piotroski F-Score
5 5 5 5
ROA
2.18% 10.60% 16.02% 14.51%
ROIC
5.62% 24.56% 36.84% 29.26%
Return on Tangible Assets
3.63% 15.31% 22.29% 20.27%
Average Days of Receivables
42.44 43.15 66.01 72.53
Free Cash Flow per Share
0.30 0.47 0.49 0.45
Free Cash Flow
44.43 69.31 72.97 66.81
Other line items

Show all line items

Columns are period end dates